{"product_id":"navb-vrio-analysis","title":"Navidea Biopharmaceuticals, Inc. (NAVB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Navidea Biopharmaceuticals, Inc. (NAVB) truly built to last? We've subjected its core assets to the rigorous VRIO framework - assessing its Value, Rarity, Inimitability, and Organization - to uncover the definitive source of its competitive edge, or lack thereof. Dive into this distilled analysis below to see precisely where Navidea Biopharmaceuticals, Inc. (NAVB) stands in the market and what it takes to secure a sustainable advantage.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Manocept Technology Platform (Core IP)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core intellectual property of Navidea Biopharmaceuticals, the Manocept platform, right as the company is navigating a major financial hurdle. Honestly, the science itself is compelling, but the current organizational state casts a long shadow over its immediate potential.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eManocept Technology Platform (Core IP) Assessment\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The platform provides the molecular backbone for targeted diagnostics and therapeutics by specifically hitting the CD206 mannose receptor on activated macrophages. This aims to improve patient care by better identifying disease pathways, which is a high-value proposition in precision medicine. The lead product, Tc99m tilmanocept, is already commercialized for lymphatic mapping, demonstrating a tangible, albeit currently underperforming, value stream.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific targeting mechanism - the CD206 mannose receptor - is relatively unique in the current diagnostic and therapeutic space, especially for macrophage-centric diseases. While macrophage targeting isn't new, the validated molecular constructs built on this specific platform offer a distinct approach compared to many competitors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Imitating the general concept of CD206 targeting is certainly possible for well-funded rivals. However, replicating the specific, validated molecular constructs and the associated intellectual property portfolio without extensive reverse engineering and years of preclinical work would be difficult. The patent portfolio offers a barrier, but it's not impenetrable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e This is where the immediate value erodes. Navidea Biopharmaceuticals filed for Chapter 11 bankruptcy protection on \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e, to pursue an orderly financial restructuring. This filing means the organization is currently focused on debt and creditor management, which severely hinders its ability to immediately exploit the Manocept platform's potential through new partnerships or development. Furthermore, disappointing data from the RA Trial showed predictive accuracy for treatment response was consistently below \u003cstrong\u003e70%\u003c\/strong\u003e, leading the company to suspend RA-related activities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Currently, the advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. The core science holds inherent value and rarity, but the bankruptcy filing effectively caps the organization's capacity to leverage this asset effectively right now. The focus shifts from market penetration to financial survival and asset preservation.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how the VRIO elements stack up for the Manocept platform:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Context (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eMolecular backbone for targeted diagnostics\/therapeutics; Lead product Tc99m tilmanocept commercialized.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eSpecific targeting of the CD206 mannose receptor is relatively unique in the current diagnostic space.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eSpecific, validated molecular constructs require reverse engineering; IP portfolio exists.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eNo (Currently)\u003c\/td\u003e\n\u003ctd\u003eChapter 11 bankruptcy filed \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e; RA Trial predictive accuracy below \u003cstrong\u003e70%\u003c\/strong\u003e led to activity suspension.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eValue and Rarity exist, but organizational distress prevents sustained exploitation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the potential value locked in the therapeutic pipeline assets that Navidea intends to evaluate during the restructuring process. If a partner steps in, the 'Organization' component could flip quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTarget: CD206 mannose receptor on activated macrophages.\u003c\/li\u003e\n\u003cli\u003ePlatform versatility: SPECT, PET, intra-operative imaging potential.\u003c\/li\u003e\n\u003cli\u003ePipeline focus shift: Pivoting to explore therapeutic assets post-RA Trial disappointment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft a scenario analysis on asset valuation under the Subchapter V restructuring plan by next Tuesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Tc99m Tilmanocept (Lead Asset IP)\n\u003c\/h2\u003e\n\u003cp\u003eTc99m Tilmanocept (Lead Asset IP)\u003c\/p\u003e\n\u003cp\u003e\n    \u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eIt is the first commercialized product based on the platform, representing validated proof-of-concept and existing regulatory pathways. The North American rights were sold to Cardinal Health in March 2017 for approximately \u003cstrong\u003e$82 million\u003c\/strong\u003e at closing. The agreement allows for up to \u003cstrong\u003e$227 million\u003c\/strong\u003e of contingent consideration through 2026.\u003c\/p\u003e\n\u003ctable\u003e\n    \u003cthead\u003e\n        \u003ctr\u003e\n            \u003cth\u003eMetric\u003c\/th\u003e\n            \u003cth\u003eValue\u003c\/th\u003e\n            \u003cth\u003eDate\/Context\u003c\/th\u003e\n        \u003c\/tr\u003e\n    \u003c\/thead\u003e\n    \u003ctbody\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eNorth American Rights Sale Closing Payment\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e$82 million\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003eMarch 2017\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eMaximum Contingent Consideration\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e$227 million\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003eThrough 2026\u003c\/td\u003e\n        \u003c\/tr\u003e\n        \u003ctr\u003e\n            \u003ctd\u003eGuaranteed Contingent Consideration\u003c\/td\u003e\n            \u003ctd\u003e\u003cstrong\u003e$17.1 million\u003c\/strong\u003e\u003c\/td\u003e\n            \u003ctd\u003eOver three years from March 2017\u003c\/td\u003e\n        \u003c\/tr\u003e\n    \u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n    \u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eLow rarity, as it is a single, specific radiopharmaceutical agent, but its mechanism is distinct. The Manocept platform is predicated on the ability to specifically target the \u003cstrong\u003eCD206 mannose receptor\u003c\/strong\u003e expressed on activated macrophages.\u003c\/p\u003e\n\u003cp\u003e\n    \u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eMedium imitatibility; competitors could develop similar agents, but replicating the specific clinical\/regulatory history is hard. The first composition of matter patent covering tilmanocept was issued in the United States in June 2002 and would have expired in May 2020.\u003c\/p\u003e\n\u003cp\u003e\n    \u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eOrganization is focused on preserving asset value during restructuring, meaning commercialization efforts are likely paused or minimal. Navidea filed a voluntary petition for Chapter 11 bankruptcy on October 1, 2025, intending to pursue an orderly restructuring while continuing \u003cstrong\u003elimited operations to preserve value\u003c\/strong\u003e for creditors and stakeholders. The stock price as of October 2025 was reported as \u003cstrong\u003e$0.00\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eShares of Common Stock outstanding as of March 17, 2023: \u003cstrong\u003e32,851,252\u003c\/strong\u003e.\u003c\/li\u003e\n    \u003cli\u003eU.S. federal Net Operating Loss Carryforwards (NOLs) as of December 31, 2024: approximately \u003cstrong\u003e$170 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n    \u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary. Its value is tied to its existing status, which is threatened by the financial distress. The company is developing multiple precision-targeted products based on its Manocept platform.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Diverse Portfolio of Issued US and Foreign Patents\n\u003c\/h2\u003e\n\n\u003cp\u003eThe intellectual property portfolio, including US and international patents, is a core asset being protected during the Chapter 11 restructuring initiated on \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe portfolio provides legal protection for the Manocept platform and pipeline assets, including the commercialized product \u003cstrong\u003eTc99m tilmanocept\u003c\/strong\u003e. The company reported total assets of \u003cstrong\u003e$1.2 million\u003c\/strong\u003e as of the filing date.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe portfolio includes patents covering the Manocept platform, which targets the CD206 mannose receptor. Specific granted patents include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUS Patent with issue date \u003cstrong\u003eJune 11, 2024\u003c\/strong\u003e (Patent number: 12006339).\u003c\/li\u003e\n\u003cli\u003eUS Patent with issue date \u003cstrong\u003eJune 11, 2024\u003c\/strong\u003e (Patent number: 12005122).\u003c\/li\u003e\n\u003cli\u003eUS Patent with issue date \u003cstrong\u003eSeptember 2, 2025\u003c\/strong\u003e (related to amide linkage).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\/Patent Focus\u003c\/th\u003e\n\u003cth\u003ePatent Number Example\u003c\/th\u003e\n\u003cth\u003eIssue Date Example\u003c\/th\u003e\n\u003cth\u003eStatus Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLymphoseek Protection\u003c\/td\u003e\n\u003ctd\u003e6,409,990\u003c\/td\u003e\n\u003ctd\u003eExtended through \u003cstrong\u003eMay 12, 2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eExclusive rights extension.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCD206 Targeting\/Linker\u003c\/td\u003e\n\u003ctd\u003e12006339\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 11, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eViral Infection Treatment\u003c\/td\u003e\n\u003ctd\u003e12005122\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 11, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmide Linkage Stability\u003c\/td\u003e\n\u003ctd\u003eN\/A (Filed Oct 3, 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSeptember 2, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePatents create legal barriers to entry for specific claims. The portfolio includes intellectual property rights under the \u003cstrong\u003eVera Patents\u003c\/strong\u003e. The legal team is organized to defend these assets, which are key for potential future licensing deals.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe company filed for relief under Chapter 11, Subchapter V in the U.S. Bankruptcy Court for the District of Delaware on \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e. The stated intent is to explore strategic alternatives and protect assets while managing liabilities of \u003cstrong\u003e$12.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe existence of granted patents, such as the extension for U.S. patent 6,409,990 until \u003cstrong\u003eMay 12, 2025\u003c\/strong\u003e, provides a long-term moat for the Manocept technology platform.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Potential Cardinal Health Milestone Payments\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the contingent consideration stream derived from the North American rights sale of Lymphoseek® to Cardinal Health.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePotential future consideration streams from the North American rights sale of Lymphoseek® to Cardinal Health, as per the original agreement, included an opportunity for up to \u003cstrong\u003e\\$227 million\u003c\/strong\u003e in milestone payments through \u003cstrong\u003e2026\u003c\/strong\u003e. The initial closing payment received was approximately \u003cstrong\u003e\\$83 million\u003c\/strong\u003e. As of June 2023, Navidea received \u003cstrong\u003e\\$7.5 million\u003c\/strong\u003e cash from Cardinal Health in lieu of a specific contingent Milestone Payment.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eContingent payments are standard in pharmaceutical licensing agreements; however, the specific structure and quantum tied to Lymphoseek® are unique to Navidea's asset portfolio. The initial guaranteed portion was reported as \u003cstrong\u003e\\$17.1 million\u003c\/strong\u003e over the first three years post-closing. The total potential consideration was initially reported as up to \u003cstrong\u003e\\$230 million\u003c\/strong\u003e in some sources.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThis stream is a contractual right, not an internally developed, inimitable capability. The right is defined by the Asset Purchase Agreement executed in \u003cstrong\u003e2016\/2017\u003c\/strong\u003e. The contractual nature makes the right itself easily imitable via contract, though the underlying asset (Lymphoseek®) is not.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eActive management by finance and legal teams is required to track and enforce the realization of these payments. The company has demonstrated active management by executing amendments to secure immediate capital:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIntent to sell a Cardinal Milestone Payment for \u003cstrong\u003e\\$8 million\u003c\/strong\u003e announced in April \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReceipt of \u003cstrong\u003e\\$7.5 million\u003c\/strong\u003e cash from Cardinal Health in June \u003cstrong\u003e2023\u003c\/strong\u003e in exchange for waiving a specific contingent Milestone Payment.\u003c\/li\u003e\n\u003cli\u003eThe initial closing payment was approximately \u003cstrong\u003e\\$83 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe following table summarizes key financial figures related to the transaction:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum Potential Milestones\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e\\$227 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eThrough \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Closing Payment Received\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e\\$83 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eClosing (\u003cstrong\u003e2017\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuaranteed Initial Milestones\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$17.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOver the first three years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Received in Lieu of Milestone\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$7.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e due to the time-bound nature of the agreement, expiring around \u003cstrong\u003e2026\u003c\/strong\u003e. The asset is external and non-renewable, unlike core competencies such as proprietary technology platforms. The company's ability to secure immediate cash against future receivables (e.g., the \u003cstrong\u003e\\$7.5 million\u003c\/strong\u003e payment) demonstrates leveraging this asset for near-term operational funding.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Net Operating Loss (NOL) Tax Assets\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSignificant potential to offset future taxable income, a major draw for a profitable acquirer post-restructuring. The value is quantified by the available tax attributes as of December 31, 2024, which included approximately $170 million in U.S. federal Net Operating Losses (NOLs) and approximately $9 million in Research \u0026amp; Development (R\u0026amp;D) tax credits that may be used to offset future federal taxable income.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTax Asset Category\u003c\/th\u003e\n\u003cth\u003eAmount (as of 12\/31\/2024)\u003c\/th\u003e\n\u003cth\u003ePotential Use\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Federal NOLs\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$170 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOffset future federal taxable income\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Tax Credits\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOffset future federal tax liability\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nMedium rarity; many pre-profit biotechs carry these, but the size is company-specific. The $170 million NOL balance is a significant quantum for a company of this stage.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nLow imitability; these are historical accounting facts, not replicable processes. The NOLs result from historical operating losses.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe Board is organized to protect these assets from being lost under Internal Revenue Service (IRS) rules, specifically Section 382 limitations. The organization is evidenced by:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe extension of the Section 382 Rights Agreement to April 7, 2027, which deters ownership change by limiting any person or group from acquiring beneficial ownership of 4.99% or more of common stock.\u003c\/li\u003e\n\u003cli\u003eThe extension of authority to implement a reverse stock split of up to 1-for-50,000 shares, which was extended to July 8, 2027.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\nThe rationale for the reverse split authority includes simplifying the capitalization table and reducing the number of record holders to stay below SEC public reporting thresholds, which entails significant costs.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSustained. If protected through the Section 382 Rights Plan, these are a powerful, non-core financial advantage. The protection mechanism is active until April 7, 2027.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Chapter 11 Restructuring Process\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The filing under Chapter 11, Subchapter V of the U.S. Bankruptcy Code on \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e, allows for an orderly restructuring of financial obligations while continuing limited operations to preserve asset value for creditors.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low rarity for a company of this size, but the specific legal strategy under Subchapter V is unique to this case. The company's lead product, Tc99m tilmanocept, had its North American rights sold in 2017 for \u003cstrong\u003e\\$83 million\u003c\/strong\u003e at closing, with \u003cstrong\u003e\\$227 million\u003c\/strong\u003e earmarked based on milestones through 2026.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low imitatibility; it’s a legal status, not a business process. The case is being heard in the U.S. Bankruptcy Court for the District of Delaware.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The engagement of Epiq Corporate Restructuring, LLC shows a clear, organized structure for managing the court-supervised process. The company's equity security holders include John K. Scott, Jr. holding approximately \u003cstrong\u003e54%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCase Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiling Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChapter Filing\u003c\/td\u003e\n\u003ctd\u003eChapter 11, Subchapter V\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCase Number\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25-11779\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$12.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey dates established for the process include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst Day Hearing: \u003cstrong\u003eOctober 2, 2025\u003c\/strong\u003e, 02:00 PM ET.\u003c\/li\u003e\n\u003cli\u003e341 Meeting of Creditors: \u003cstrong\u003eNovember 14, 2025\u003c\/strong\u003e at 10:00 AM ET.\u003c\/li\u003e\n\u003cli\u003eGeneral Bar Date for Claims: \u003cstrong\u003eDecember 1, 2025\u003c\/strong\u003e 11:59 p.m. (ET).\u003c\/li\u003e\n\u003cli\u003eGovernmental Bar Date: \u003cstrong\u003eMarch 30, 2026\u003c\/strong\u003e 11:59 p.m. (ET).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a necessary, but temporary, legal tool to survive, not a source of ongoing market advantage. The company intends to use the Chapter 11 process to evaluate strategic alternatives and protect its assets.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Precision Medicine Strategic Focus\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003ePrecision Medicine Strategic Focus\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eMaintains a clear, high-value focus on next-generation targeted diagnostics and therapies for cancer and inflammatory diseases, predicated on the Manocept™ platform which specifically targets the CD206 mannose receptor expressed on macrophages. The platform is the molecular backbone for the FDA-approved diagnostic agent, Lymphoseek® (technetium Tc 99m tilmanocept), approved by the FDA in March 2013 and by the EMA in November 2014. The platform is also being used to develop therapeutics like MT-1001 (with doxorubicin) and MT-2001 (with an anti-inflammatory agent).\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eMedium rarity; many firms are in precision medicine, but Navidea’s specific macrophage targeting niche via the CD206 receptor is less crowded. The technology is designed to selectively deliver agents to kill or alter disease-associated macrophages.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eMedium imitatibility; the strategic direction is easy to copy, but the deep institutional knowledge and the portfolio of U.S. and international patents related to the Manocept platform are harder to replicate.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe focus remains stated, but operational capacity is severely constrained by the bankruptcy filing. Navidea filed a voluntary petition for relief under Chapter 11, Subchapter V of the United States Bankruptcy Code on October 1, 2025, intending to pursue orderly restructuring while continuing \u003cstrong\u003elimited operations\u003c\/strong\u003e to preserve value.\u003c\/p\u003e\n\u003cp\u003eThe financial structure at the time of filing indicated reported \u003cstrong\u003e$1.2 million in assets\u003c\/strong\u003e and \u003cstrong\u003e$12.9 million in liabilities\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperational Status\u003c\/td\u003e\n\u003ctd\u003eChapter 11 Filing Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Constraint (Filing)\u003c\/td\u003e\n\u003ctd\u003eReported Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Constraint (Filing)\u003c\/td\u003e\n\u003ctd\u003eReported Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Application\u003c\/td\u003e\n\u003ctd\u003eFDA Approval (Lymphoseek®)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 2013\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology Application\u003c\/td\u003e\n\u003ctd\u003eEMA Approval (Lymphoseek®)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 2014\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical R\u0026amp;D (Pre-Filing)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (9 Months Ended Sep 30, 2021)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Liquidity (Pre-Filing)\u003c\/td\u003e\n\u003ctd\u003eCash and Equivalents (End of Q3 2021)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary. The focus itself is not a barrier, but the underlying science - the patented Manocept platform's ability to specifically target CD206 on activated macrophages - is the true, albeit currently constrained, advantage. The company is pursuing global partnerships to advance its development strategy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eManocept platform is designed for applications in:\n\u003cul\u003e\n\u003cli\u003eCancer\u003c\/li\u003e\n\u003cli\u003eAutoimmune disorders (e.g., Rheumatoid Arthritis)\u003c\/li\u003e\n\u003cli\u003eInflammatory diseases\u003c\/li\u003e\n\u003cli\u003eCentral Nervous System (CNS) diseases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Management and Board Expertise in Radiopharmaceuticals\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eManagement and Board Expertise in Radiopharmaceuticals\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: Possesses leaders experienced in the complex research, development, and commercialization of precision diagnostic and radiopharmaceutical imaging agents.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: Medium rarity; specialized expertise in this niche is not common, though the current team’s effectiveness is under strain.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: Medium imitatibility; hiring experienced personnel is possible, but retaining institutional memory is difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: The team is still in place, directing the restructuring, which suggests a commitment to preserving the core scientific talent.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary. Talent can leave, especially during bankruptcy, making this a fragile, time-sensitive resource.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eRole\/Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003ctd\u003eDate\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Financial Officer Experience\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e30 years\u003c\/strong\u003e in finance and leadership\u003c\/td\u003e\n\u003ctd\u003eRecent Profile\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoard Member Loan\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$750,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExisting Note Principal Forgiveness\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContingent Liability (Settled)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,711,806\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Coverage\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7\u003c\/strong\u003e analysts\u003c\/td\u003e\n\u003ctd\u003eRecent Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Revenue\/Earnings Estimates\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRecent Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eRecent governance and financial restructuring data points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBoard authorized Consulting Services Agreement with G2G Ventures on \u003cstrong\u003eNovember 10, 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eJohn K. Scott Jr. elected as director with \u003cstrong\u003e43,361,812\u003c\/strong\u003e votes cast for him.\u003c\/li\u003e\n\u003cli\u003eCompany filed Form 15 to suspend SEC reporting obligations on \u003cstrong\u003eJanuary 26, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCompany filed for Bankruptcy on \u003cstrong\u003eOctober 8, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eReverse stock split authority extended to July 8, \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNavidea Biopharmaceuticals, Inc. (NAVB) - VRIO Analysis: Existing Royalty Revenue Stream\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eExisting Royalty Revenue Stream\u003c\/h\u003e\n\u003c\/p\u003e\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eVRIO Component\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eAssessment\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eData\/Metric\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eProvides a small, ongoing, non-dilutive cash inflow.\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e\\$14.65K\u003c\/strong\u003e TTM as of Q3 2023, representing \u003cstrong\u003e100%\u003c\/strong\u003e royalty revenue.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eLow rarity; many companies have some royalty income, but the amount is minimal.\u003c\/td\u003e\n    \u003ctd\u003eTotal Revenue (TTM Sep 30, 2023) was \u003cstrong\u003e\\$610.00\u003c\/strong\u003e.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eImitatibility\u003c\/td\u003e\n    \u003ctd\u003eLow imitatibility; it’s a contractual income stream from past deals.\u003c\/td\u003e\n    \u003ctd\u003eIncome stream is based on existing licensing agreements.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eThe organization is organized to collect this, as it is an automated function of the existing licensing agreements.\u003c\/td\u003e\n    \u003ctd\u003eCollection is an automated function of established contracts.\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary. It’s a small, finite stream that won't fund significant operations but helps cover minimal overhead.\u003c\/td\u003e\n    \u003ctd\u003eStream is finite and insufficient for major operational funding.\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eLatest Relevant Financial Data Points:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eShares of Common Stock outstanding as of November 10, 2023: \u003cstrong\u003e100,084,385\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eContingent liability for judgment and accrued interest as of September 30, 2023: \u003cstrong\u003e\\$2,711,806\u003c\/strong\u003e, which was resolved via a settlement agreement.\u003c\/li\u003e\n  \u003cli\u003eChapter 11 Subchapter V filing date: \u003cstrong\u003eOctober 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eReported Assets as of October 1, 2025 filing: \u003cstrong\u003e\\$1.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eReported Liabilities as of October 1, 2025 filing: \u003cstrong\u003e\\$12.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eMEMORANDUM\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eTO:\u003c\/strong\u003e Restructuring Officer\u003cbr\u003e\n\u003cstrong\u003eFROM:\u003c\/strong\u003e Financial Analysis Team\u003cbr\u003e\n\u003cstrong\u003eDATE:\u003c\/strong\u003e [Current Date]\u003cbr\u003e\n\u003cstrong\u003eSUBJECT:\u003c\/strong\u003e Potential Impact of \u003cstrong\u003e\\$227 Million\u003c\/strong\u003e Milestone Payments on Post-Chapter 11 Capitalization Plan\n\u003c\/p\u003e\n\u003cp\u003e\nThis memo details the potential impact of realizing \u003cstrong\u003e\\$227,000,000\u003c\/strong\u003e in milestone payments on the post-Chapter 11 capitalization structure, to be finalized by next Wednesday.\n\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe potential inflow of \u003cstrong\u003e\\$227.0 million\u003c\/strong\u003e represents a significant capital infusion relative to the reported pre-filing liabilities of \u003cstrong\u003e\\$12.9 million\u003c\/strong\u003e as of October 1, 2025.\u003c\/li\u003e\n  \u003cli\u003eThis magnitude of cash availability would fundamentally alter the priority of claims and the potential recovery rates for all creditor classes, particularly unsecured creditors who were indicated to have funds available for distribution.\u003c\/li\u003e\n  \u003cli\u003eThe capitalization plan must model scenarios where this cash is used for:\u003c\/li\u003e\n  \u003cul\u003e\n    \u003cli\u003eFull satisfaction of all allowed claims, including secured and unsecured creditors.\u003c\/li\u003e\n    \u003cli\u003ePotential funding for ongoing operations post-emergence, independent of the \u003cstrong\u003e\\$14.65K\u003c\/strong\u003e royalty stream.\u003c\/li\u003e\n    \u003cli\u003eConsideration for warrants or equity stakes issued to pre-petition lenders or new capital providers, contingent on the terms of the Loan Agreement entered into for the CRG settlement.\u003c\/li\u003e\n  \u003c\/ul\u003e\n  \u003cli\u003eThe timing of the milestone receipt relative to the confirmation date of the Chapter 11 Plan of Reorganization is critical for determining the final capital structure and the treatment of existing equity (\u003cstrong\u003e100,084,385\u003c\/strong\u003e shares as of November 10, 2023).\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516213878933,"sku":"navb-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/navb-vrio-analysis.png?v=1740197995","url":"https:\/\/dcf-model.com\/pt\/products\/navb-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}